Human Immunoglobulin G

CHEMBL1201599 Phase 4 Đã phê duyệt Unknown
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This preparation contains protective antibodies derived from donated human plasma, used to supplement or replace the immune defenses of people who cannot make adequate antibodies on their own. It is administered to treat immune deficiencies and certain autoimmune or inflammatory conditions.

Lĩnh vực điều trị

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This preparation contains protective antibodies derived from donated human plasma, used to supplement or replace the immune defenses of people who cannot make adequate antibodies on their own. It is administered to treat immune deficiencies and certain autoimmune or inflammatory conditions.

Yes, Human Immunoglobulin G is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201599. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.